Kexing Biopharm's Licensed-In Generic Paclitaxel for Injection (Albumin-Bound) Receives Marketing Approval in Georgia

Article source：Kexing BiopharmNov 06,2025View： 153

Recently, Kexing Biopharm (stock code: 688132.SH) has officially received marketing approval from the Georgian Medicines and Pharmaceutical Agency for its licensed-in generic product, Paclitaxel for Injection (Albumin-Bound). This marks the first marketing authorization for the product in the South Caucasus region, laying a solid foundation for subsequent deep penetration into the regional pharmaceutical market.

The albumin-bound paclitaxel, developed in collaboration with Haichang Biotech, has experienced rapid commercialization since its approval in the European Union last year. The stringent EU certification standards have effectively facilitated the product's entry into emerging markets, with recent approvals secured in multiple countries, including Peru, Oman, and Uruguay.

Looking ahead, Kexing Biopharm will continue to advance the overseas access and marketing efforts for its export products, while deepening collaborations with local healthcare systems to bring high-quality domestic medicines to more patients.